×
0 0 0 0 0.02 0.02 -0.0164 -0.0547999999999999
Stockreport

Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

Puma Biotech, Inc (PBYI)  More Company Research Source: Business Wire
Last puma biotech, inc earnings: 11/1 04:10 pm Check Earnings Report
US:NYSE Investor Relations: pumabiotechnology.com/ir.html
PDF LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada. Puma Biotechnology filed a new drug submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada. Puma will receive upfront and milestone payments up to $7.2 million USD throughout the term of this agreement, as well as double digit royalties on net sales of NERLYNX in Canada. “Our new agreement with [Read more]

IMPACT SNAPSHOT EVENT TIME: PBYI
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
PBYI alerts
from News Quantified
Opt-in for
PBYI alerts

from News Quantified
Opt-in for
PBYI alerts

from News Quantified